Table 1.
Baseline characteristics and outcomes by testican-2 tertile in AASK, CRIC, and ARIC
| AASK | CRIC | ARIC | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Characteristic | Total (n=703) | Tertile 1 | Tertile 2 | Tertile 3 | P | Total (n=3196) | Tertile 1 | Tertile 2 | Tertile 3 | P | Total (n=4378) | Tertile 1 | Tertile 2 | Tertile 3 | P |
| Age, yr | 54.5±10.7 | 53.2±11.0 | 53.9±11.1 | 54.4±16.9 | 0.48 | 59.1±10.7 | 57.9±11.3 | 59.8±10.7 | 59.5±9.8 | <0.001 | 75.7±5.2 | 76.4±5.3 | 75.6±5.2 | 75.2±4.9 | <0.001 |
| Black, % | 1322 (41.4) | 451 (42.3) | 423 (39.7) | 448 (42.1) | 0.91 | 823 (18.8) | 320 (21.9) | 260 (17.8) | 243 (16.7) | <0.001 | |||||
| Woman, % | 38.6 | 40.4 | 38.9 | 36.3 | 0.73 | 44.6 | 46.0 | 43.0 | 44.7 | 0.56 | 54.9 | 55 | 57 | 53 | 0.20 |
| Heart disease, % | 50.9 | 45.5 | 54.3 | 53.0 | 0.059 | 35.3 | 36.1 | 36.1 | 33.7 | 0.25 | 18.5 | 22 | 16 | 18 | 0.008 |
| Diabetes, % | — | — | — | — | — | 48.7 | 55.6 | 50.5 | 40.0 | <0.001 | 30.0 | 37 | 28 | 25 | <0.001 |
| TC, mg/dl | 211.9±45.7 | 210.8±47.2 | 213.4±43.7 | 211.6±46.2 | 0.53 | 181.6±43.4 | 179.8±43.9 | 180.9±43.9 | 184.1±42.4 | 0.026 | 179.4±41.6 | 177.4±43.2 | 181.2±41.1 | 179.6±40.4 | 0.16 |
| HDL, mg/dl | 48.3±16.0 | 47.0±16.1 | 47.5±15.4 | 50.3±16.3 | 0.77 | 48.6±15.8 | 46.0±15.0 | 48.1±15.2 | 51.6±16.5 | <0.001 | 51.4±14.0 | 49.2±13.3 | 51.8±13.7 | 53.1±14.4 | <0.001 |
| SBP, mm Hg | 151.1±24.9 | 149.9±22.6 | 150.3±26.0 | 153.2±25.8 | 0.84 | 126.8±21.6 | 130.3±22.5 | 126.2±21.4 | 124.0±20.5 | <0.001 | 130.5±18.1 | 131.8±18.9 | 130.4±17.9 | 129.1±17.5 | <0.001 |
| BMI, kg/m2 | 30.5±6.4 | 30.8±6.7 | 30.5±6.4 | 30.4±6.2 | 0.57 | 32.1±7.7 | 32.7±8.6 | 32.0±7.4 | 31.7±7.0 | 0.004 | 28.8±5.6 | 29.2±6.0 | 28.8±5.7 | 28.2±5.1 | <0.001 |
| eGFR,a ml/min per 1.73 m2 | 45.7±13.0 | 39.6±12.8 | 46.2±12.4 | 51.3±11.1 | <0.001 | 42.8±15.9 | 33.0±13.5 | 43.6±13.9 | 51.6±14.6 | <0.001 | 65.0±17.8 | 55.0±17.6 | 66.7±15.2 | 73.1±15.5 | <0.001 |
| PCR, g/g | 0.33±0.52 | 0.49±0.62 | 0.31±0.50 | 0.18±0.37 | <0.001 | 0.79±1.77 | 1.40±2.53 | 0.61±1.34 | 0.40±0.93 | <0.001 | |||||
| ACR, g/g | 0.05±0.28 | 0.09±0.44 | 0.03±0.14 | 0.04±0.17 | <0.001 | ||||||||||
| CKD progression, n (%) | 274 (39.0) | 125 (53.2) | 91 (38.9) | 58 (24.8) | 0.002 | 1222 (38.4) | 594 (55.7) | 385 (36.1) | 243 (22.8) | <0.001 | 69 (1.4) | 43 (2.7) | 15 (1.0) | 11 (0.8) | <0.001 |
| Follow-up time, yr | 7.02 (3.45) | 6.86 (4.98) | 5.22 (1.24) | ||||||||||||
| ESKD incident, n (%) | 210 (29.9) | 110 (46.8) | 70 (29.9) | 30 (12.8) | <0.001 | 1028 (32.2) | 552 (51.8) | 302 (28.3) | 174 (16.3) | <0.001 | 31 (0.7) | 27 (1.8) | <11 | <11 | <0.001 |
| Follow-up time, yr | 7.49 (3.36) | 9.04 (4.98) | 5.23 (1.24) | ||||||||||||
Values are mean±SD or percentage. For proteinuria, values are mean PCR±SD for AASK and CRIC; and mean ACR±SD for ARIC. AASK, American Study of Kidney Disease and Hypertension; ARIC, Atherosclerosis Risk in Communities; CRIC, Chronic Renal Insufficiency Cohort; TC, total cholesterol; SBP, systolic BP; BMI, body mass index; PCR, urine protein/creatinine ratio; ACR, urine albumin/creatinine ratio.
a
In AASK, GFR was directly measured.